Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
128 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Acute Coronary Syndrome - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Acute Coronary Syndrome - Pipeline Review, H2 2014', provides an overview of the Acute Coronary Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Coronary Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Coronary Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Acute Coronary Syndrome Overview 9 Therapeutics Development 10 Pipeline Products for Acute Coronary Syndrome - Overview 10 Pipeline Products for Acute Coronary Syndrome - Comparative Analysis 11 Acute Coronary Syndrome - Therapeutics under Development by Companies 12 Acute Coronary Syndrome - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Acute Coronary Syndrome - Products under Development by Companies 18 Acute Coronary Syndrome - Companies Involved in Therapeutics Development 20 AstraZeneca PLC 20 GlaxoSmithKline plc 21 MedImmune, LLC 22 The Medicines Company 23 Pfizer Inc. 24 Bayer AG 25 Ligand Pharmaceuticals, Inc. 26 Arena Pharmaceuticals, Inc. 27 CSL Limited 28 XOMA Corporation 29 Auspex Pharmaceuticals, Inc. 30 Regado Biosciences, Inc. 31 Vitae Pharmaceuticals, Inc. 32 Athera Biotechnologies AB 33 Lacer, S.A. 34 Lee's Pharmaceutical Holdings Limited 35 Esperion Therapeutics, Inc. 36 Artery Therapeutics, Inc. 37 advanceCor GmbH 38 Acute Coronary Syndrome - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 43 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 rivaroxaban - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 cangrelor - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BAY-818781 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 clopidogrel bisulfate - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 CSL-112 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 gevokizumab - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 MTP-131 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 ZK-001 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 PR-15 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 temanogrel hydrochloride - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 MDCO-216 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 losmapimod - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 MEDI-6012 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 PF-06282999 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 SD-970 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 tirofiban hydrochloride - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 PC-mAb - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 LA-8045 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 COR-3 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 COR-2 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 AEM-28 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 bivalirudin - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 PMC-6 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 4-WF - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 VTP-38443 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Artpep-2 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 AEM-28 Analogs - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Aptamers for Cardiovascular Diseases - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Acute Coronary Syndrome - Recent Pipeline Updates 92 Acute Coronary Syndrome - Dormant Projects 115 Acute Coronary Syndrome - Discontinued Products 116 Acute Coronary Syndrome - Product Development Milestones 117 Featured News & Press Releases 117 Jul 23, 2014: Daiichi Sankyo and Eli Lilly and Company: Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel 117 Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome 118 May 13, 2014: GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome 118 May 08, 2014: FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients 119 Jan 16, 2014: FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome 120 Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001 121 Sep 03, 2013: Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published 122 Jul 24, 2013: Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine 123 Jun 28, 2013: FDA Issues Complete Response Letter for XARELTO to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome 123 Jun 24, 2013: Bayer To Present New Data On Clinical Benefit Of Xarelto At ISTH 2013 124 Appendix 127 Methodology 127 Coverage 127 Secondary Research 127 Primary Research 127 Expert Panel Validation 127 Contact Us 128 Disclaimer 128
List of Tables Number of Products under Development for Acute Coronary Syndrome, H2 2014 10 Number of Products under Development for Acute Coronary Syndrome - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Development by Companies, H2 2014 (Contd..1) 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Products under Development by Companies, H2 2014 18 Products under Development by Companies, H2 2014 (Contd..1) 19 Acute Coronary Syndrome - Pipeline by AstraZeneca PLC, H2 2014 20 Acute Coronary Syndrome - Pipeline by GlaxoSmithKline plc, H2 2014 21 Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H2 2014 22 Acute Coronary Syndrome - Pipeline by The Medicines Company, H2 2014 23 Acute Coronary Syndrome - Pipeline by Pfizer Inc., H2 2014 24 Acute Coronary Syndrome - Pipeline by Bayer AG, H2 2014 25 Acute Coronary Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 26 Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H2 2014 27 Acute Coronary Syndrome - Pipeline by CSL Limited, H2 2014 28 Acute Coronary Syndrome - Pipeline by XOMA Corporation, H2 2014 29 Acute Coronary Syndrome - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 30 Acute Coronary Syndrome - Pipeline by Regado Biosciences, Inc., H2 2014 31 Acute Coronary Syndrome - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014 32 Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H2 2014 33 Acute Coronary Syndrome - Pipeline by Lacer, S.A., H2 2014 34 Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 35 Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H2 2014 36 Acute Coronary Syndrome - Pipeline by Artery Therapeutics, Inc., H2 2014 37 Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H2 2014 38 Assessment by Monotherapy Products, H2 2014 39 Number of Products by Stage and Target, H2 2014 42 Number of Products by Stage and Mechanism of Action, H2 2014 45 Number of Products by Stage and Route of Administration, H2 2014 47 Number of Products by Stage and Molecule Type, H2 2014 49 Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 92 Acute Coronary Syndrome - Dormant Projects, H2 2014 115 Acute Coronary Syndrome - Discontinued Products, H2 2014 116
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
